Physician profile
John N Figel
NPI 1336146448
$3,247.04
in general payments reported to CMS, 2019-2025
24 companies · $683 in 2025
The $683 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $295 · 2021: $389 · 2022: $572 · 2023: $579 · 2024: $590 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,852.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $985.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $354.42 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $285.83 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.47 | 2021-2025 | Jardiance |
| Amgen INC. | $228.80 | 2020-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $146.43 | 2022-2025 | |
| Abbvie INC. | $123.28 | 2024-2025 | |
| Pfizer INC. | $120.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $92.88 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $88.30 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $73.39 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $63.05 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $59.26 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $56.90 | 2019-2024 | Xtandi |
| Exact Sciences Corporation | $42.81 | 2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.24 | 2022-2024 | Eliquis |
| Medtronic Vascular, INC. | $39.86 | 2019 | |
| Xeris Pharmaceuticals, INC. | $39.76 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $39.28 | 2024 | Voquezna |
| Amarin Pharma, INC. | $32.35 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $27.29 | 2020-2021 | |
| Tesaro, INC. | $15.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2022 | |
| Merck Sharp & Dohme LLC | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Figel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.